Long term survival of HER2-positive early breast cancer treated withtrastuzumab-based adjuvant regimen: A large cohort study fromclinical practice

Martina Bonifazi, Matteo Franchi, Marta Rossi, Alberto Zambelli, Lorenzo Moja, Antonella Zambon, Giovanni Corrao, Carlo La Vecchia, Carlo Zocchetti, Eva Negri

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Trastuzumab-based regimens for the adjuvant treatment of HER2-positive early breast cancer significantly prolonged overall survival (OS) and disease free survival (DFS) in large randomized trials, with sustained benefits at four-year follow-up. We assessed long-term survival estimates and predictors in a large cohort of Italian women with early breast cancer treated with trastuzumab in clinical practice. Through a record linkage between five regional healthcare databases, we identified women treated with trastuzumab for early breast cancer in Lombardy (2006-2009). DFS and OS were estimated using the Kaplan-Meier method, and independent predictors were assessed using proportional hazard models. 2046 women received trastuzumab in early breast cancer adjuvant setting. Overall, the proportion of patients surviving free of disease was 93.9% at one year, 85.8% at 2 years, 79.4% at 3 years, and 75.0% at 4 years. OS estimates were 98.7%, 95.4%, 91.5% and 89.4% at 1, 2, 3 and 4 years, respectively. Significant independent predictors of worse survival outcomes were age

Original languageEnglish
Pages (from-to)573-578
Number of pages6
JournalBreast
Volume23
Issue number5
DOIs
Publication statusPublished - Oct 1 2014

Fingerprint

Cohort Studies
Breast Neoplasms
Survival
Disease-Free Survival
Proportional Hazards Models
Databases
Delivery of Health Care
Trastuzumab
Therapeutics

Keywords

  • Adjuvant therapy
  • Disease-free survival
  • Early breast cancer
  • Predictors
  • Survival
  • Trastuzumab

ASJC Scopus subject areas

  • Surgery
  • Medicine(all)

Cite this

Long term survival of HER2-positive early breast cancer treated withtrastuzumab-based adjuvant regimen : A large cohort study fromclinical practice. / Bonifazi, Martina; Franchi, Matteo; Rossi, Marta; Zambelli, Alberto; Moja, Lorenzo; Zambon, Antonella; Corrao, Giovanni; La Vecchia, Carlo; Zocchetti, Carlo; Negri, Eva.

In: Breast, Vol. 23, No. 5, 01.10.2014, p. 573-578.

Research output: Contribution to journalArticle

Bonifazi, M, Franchi, M, Rossi, M, Zambelli, A, Moja, L, Zambon, A, Corrao, G, La Vecchia, C, Zocchetti, C & Negri, E 2014, 'Long term survival of HER2-positive early breast cancer treated withtrastuzumab-based adjuvant regimen: A large cohort study fromclinical practice', Breast, vol. 23, no. 5, pp. 573-578. https://doi.org/10.1016/j.breast.2014.05.022
Bonifazi, Martina ; Franchi, Matteo ; Rossi, Marta ; Zambelli, Alberto ; Moja, Lorenzo ; Zambon, Antonella ; Corrao, Giovanni ; La Vecchia, Carlo ; Zocchetti, Carlo ; Negri, Eva. / Long term survival of HER2-positive early breast cancer treated withtrastuzumab-based adjuvant regimen : A large cohort study fromclinical practice. In: Breast. 2014 ; Vol. 23, No. 5. pp. 573-578.
@article{c412ad2f96184f50924222ac0903c06a,
title = "Long term survival of HER2-positive early breast cancer treated withtrastuzumab-based adjuvant regimen: A large cohort study fromclinical practice",
abstract = "Trastuzumab-based regimens for the adjuvant treatment of HER2-positive early breast cancer significantly prolonged overall survival (OS) and disease free survival (DFS) in large randomized trials, with sustained benefits at four-year follow-up. We assessed long-term survival estimates and predictors in a large cohort of Italian women with early breast cancer treated with trastuzumab in clinical practice. Through a record linkage between five regional healthcare databases, we identified women treated with trastuzumab for early breast cancer in Lombardy (2006-2009). DFS and OS were estimated using the Kaplan-Meier method, and independent predictors were assessed using proportional hazard models. 2046 women received trastuzumab in early breast cancer adjuvant setting. Overall, the proportion of patients surviving free of disease was 93.9{\%} at one year, 85.8{\%} at 2 years, 79.4{\%} at 3 years, and 75.0{\%} at 4 years. OS estimates were 98.7{\%}, 95.4{\%}, 91.5{\%} and 89.4{\%} at 1, 2, 3 and 4 years, respectively. Significant independent predictors of worse survival outcomes were age",
keywords = "Adjuvant therapy, Disease-free survival, Early breast cancer, Predictors, Survival, Trastuzumab",
author = "Martina Bonifazi and Matteo Franchi and Marta Rossi and Alberto Zambelli and Lorenzo Moja and Antonella Zambon and Giovanni Corrao and {La Vecchia}, Carlo and Carlo Zocchetti and Eva Negri",
year = "2014",
month = "10",
day = "1",
doi = "10.1016/j.breast.2014.05.022",
language = "English",
volume = "23",
pages = "573--578",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
number = "5",

}

TY - JOUR

T1 - Long term survival of HER2-positive early breast cancer treated withtrastuzumab-based adjuvant regimen

T2 - A large cohort study fromclinical practice

AU - Bonifazi, Martina

AU - Franchi, Matteo

AU - Rossi, Marta

AU - Zambelli, Alberto

AU - Moja, Lorenzo

AU - Zambon, Antonella

AU - Corrao, Giovanni

AU - La Vecchia, Carlo

AU - Zocchetti, Carlo

AU - Negri, Eva

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Trastuzumab-based regimens for the adjuvant treatment of HER2-positive early breast cancer significantly prolonged overall survival (OS) and disease free survival (DFS) in large randomized trials, with sustained benefits at four-year follow-up. We assessed long-term survival estimates and predictors in a large cohort of Italian women with early breast cancer treated with trastuzumab in clinical practice. Through a record linkage between five regional healthcare databases, we identified women treated with trastuzumab for early breast cancer in Lombardy (2006-2009). DFS and OS were estimated using the Kaplan-Meier method, and independent predictors were assessed using proportional hazard models. 2046 women received trastuzumab in early breast cancer adjuvant setting. Overall, the proportion of patients surviving free of disease was 93.9% at one year, 85.8% at 2 years, 79.4% at 3 years, and 75.0% at 4 years. OS estimates were 98.7%, 95.4%, 91.5% and 89.4% at 1, 2, 3 and 4 years, respectively. Significant independent predictors of worse survival outcomes were age

AB - Trastuzumab-based regimens for the adjuvant treatment of HER2-positive early breast cancer significantly prolonged overall survival (OS) and disease free survival (DFS) in large randomized trials, with sustained benefits at four-year follow-up. We assessed long-term survival estimates and predictors in a large cohort of Italian women with early breast cancer treated with trastuzumab in clinical practice. Through a record linkage between five regional healthcare databases, we identified women treated with trastuzumab for early breast cancer in Lombardy (2006-2009). DFS and OS were estimated using the Kaplan-Meier method, and independent predictors were assessed using proportional hazard models. 2046 women received trastuzumab in early breast cancer adjuvant setting. Overall, the proportion of patients surviving free of disease was 93.9% at one year, 85.8% at 2 years, 79.4% at 3 years, and 75.0% at 4 years. OS estimates were 98.7%, 95.4%, 91.5% and 89.4% at 1, 2, 3 and 4 years, respectively. Significant independent predictors of worse survival outcomes were age

KW - Adjuvant therapy

KW - Disease-free survival

KW - Early breast cancer

KW - Predictors

KW - Survival

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84908160938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908160938&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2014.05.022

DO - 10.1016/j.breast.2014.05.022

M3 - Article

C2 - 24934637

AN - SCOPUS:84908160938

VL - 23

SP - 573

EP - 578

JO - Breast

JF - Breast

SN - 0960-9776

IS - 5

ER -